Benefits of the multi-omic spectral analysis approach highlight the significant potential of the Dxcover Platform for early detection of cancer.
Glasgow, Scotland, September 18, 2023
Dxcover Limited, a clinical-stage liquid biopsy company pioneerng multi-omic spectral analysis for early detection of cancer, today announced that findings from a large-scale study focused on detection of early stage tumors across multiple cancers has been published in the British Journal of Cancer.
In the study, which recruited 2,092 patients, the Dxcover Platform differentiated cancer against non-cancer patients using Fourier Transform Infrared (FTIR) spectroscopy to analyze all macromolecules in patient serum and combined machine learning algorithms to build spectral profiles that detect breast, colorectal, kidney, lung, ovarian, pancreatic, and prostate cancer. The cancer versus asymptomatic non-cancer classification detected 64% of stage I cancers when specificity was 99%, with an overall sensitivity of 56%. When tuned for higher sensitivity, this model identified 99% of stage I cancers with a specificity of 58%.
When examining cancer against all non-cancer (including symptomatic patients), the sensitivity-tuned model enabled 90% sensitivity with 61% specificity, with detection rates of 93% for stage I, 84% for stage II, 92% for stage III and 95% for stage IV.
“This publication further underscores that Dxcover’s Multi-Omic Spectral Analysis brings significant new data in the fight to detect cancer at the earliest stage when there is the greatest opportunity to save lives. Not only that, but the simplicity of our platform means it can be deployed centrally or locally for reduced cost triage and screening applications. This is a significant step forward in our mission to democratize access to care and deliver treatment to those who need it most.” said Prof. Matthew Baker, co-founder, and Chief Technology Officer at Dxcover.
Early symptoms of many cancers can be non-specific and easily overlooked by patients and doctors. Delayed diagnosis can permit cancer metastasis and lead to poorer prognosis and increased treatment costs as therapies are typically less effective for late-stage disease. An early detection platform that is capable of detecting multiple cancer types and the precursors of cancer could rule out non-cancer patients and help prioritize at-risk patients for rapid diagnostic investigation. Dxcover has also completed a retrospective colorectal study indicating enhanced capability to detect advanced adenomas, the precursor of colorectal cancer, and will be starting a major prospective collection of samples later this year.
The article can be found online using the following link: https://www.nature.com/articles/s41416-023-02423-7
For further information, please see https://www.dxcover.com/science